Skip to main content

Publications

featured publications

  • Autologous T cell therapy for PRAME advanced solid tumors in HLA-A*02 patients: a phase 1 trial.

    Nature medicine

    Authors: Martin Wermke, Dejka M Araurjo, Manik Chatterjee, Apostolia M Tsimberidou, Tobias A W Holderried, Amir A Jazaeri, Ran Reshef, Carsten Bokemeyer, Winfried Alsdorf, Katrin Wetzko, Peter Brossart, Katrin Aslan, Linus Backert, Sebastian Bunk, Jens Fritsche, Swapna Gulde, Silvana Hengler, Norbert Hilf, Mohammad B Hossain, Jens Hukelmann, Mamta Kalra, Delfi Krishna, M Alper Kursunel, Dominik Maurer, Andrea Mayer-Mokler, Regina Mendrzyk, Ali Mohamed, Karine Pozo, Arun Satelli, Marilena Letizia, Heiko Schuster, Oliver Schoor, Claudia Wagner, Hans-Georg Rammensee, Carsten Reinhardt, Harpreet Singh-Jasuja, Steffen Walter, Toni Weinschenk, Jason J Luke, Cedrik M Britten

  • Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

    Journal for immunotherapy of cancer

    Authors: Thomas Eigentler, Ioannis Thomas, Igor Samoylenko, Michael Erdmann, Lucie Heinzerling, Sebastian Ochsenreither, Jürgen Krauss, Arjun Oberoi, Caroline Robert, Celeste Lebbe, Juan Martin-Liberal, Lukas Koch, Erika Richtig, Patrick Terheyden, Carsten Weishaupt, Peter Mohr, Yulia Semiletova, Casilda Llacer Perez, Peter Brossart, Franz Georg Bauernfeind, Michael Fluck, Artem Poltoratskiy, Marina Sekacheva, Ainara Soria, Beate Schmitt-Bormann, Marina Gonzalez, Jana Heß, Peter Wengenmayer, Tobias Seibel, Sven D Koch, Gianluca Quintini, Paula Codó, Martin Falk, Oliver Schönborn-Kellenberger, Ulrike Gnad-Vogt

  • Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic.

    Journal of cancer research and clinical oncology

    Authors: Volker Arndt, Daniela Doege, Stefan Fröhling, Peter Albers, Hana Algül, Ralf Bargou, Carsten Bokemeyer, Martin Bornhäuser, Christian H Brandts, Peter Brossart, Sara Yvonne Brucker, Tim H Brümmendorf, Hartmut Döhner, Norbert Gattermann, Michael Hallek, Volker Heinemann, Ulrich Keilholz, Thomas Kindler, Cornelia von Levetzow, Florian Lordick, Ulf Peter Neumann, Christoph Peters, Dirk Schadendorf, Stephan Stilgenbauer, Thomas Zander, Daniel Zips, Delia Braun, Thomas Seufferlein, Gerd Nettekoven, Michael Baumann

  • Salvage Autologous Transplant in Relapsed Multiple Myeloma: Long-Term Follow-Up of the Phase 3 GMMG ReLApsE Trial.

    Blood

    Authors: Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, Marc S Raab, Sandra Sauer, Maximilian Merz, Elias K Mai, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Peter Brossart, Martin Goerner, Stefan Klein, Bertram Glass, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Ivana von Metzler, Hans-Walter Lindemann, Christof Scheid, Igor-Wolfgang W Blau, Hans J Salwender, Richard Noppeney, Britta Besemer, Katja C Weisel, Hartmut Goldschmidt

  • High-dose MTX-based polychemotherapy for primary CNS lymphoma in younger patients: Long-term efficacy of the modified Bonn protocol.

    Neuro-oncology advances

    Authors: Thomas Zeyen, Johannes Weller, Matthias Schneider, Anna-Laura Potthoff, Christina Schaub, Lea Roever, Eleni Gkika, Hartmut Vatter, Tobias A W Holderried, Peter Brossart, Ulrich Herrlinger, Niklas Schaefer

  • Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.

    JAMA oncology

    Authors: Jonas Saal, Markus Eckstein, Manuel Ritter, Peter Brossart, Julian Luetkens, Jörg Ellinger, Viktor Grünwald, Michael Hölzel, Niklas Klümper

  • The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression.

    European journal of cancer (Oxford, England : 1990)

    Authors: Jonas Saal, Markus Eckstein, Manuel Ritter, Peter Brossart, Michael Hölzel, Viktor Grünwald, Niklas Klümper

  • Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.

    HemaSphere

    Authors: Elias K Mai, Axel Nogai, Henk M Lokhorst, Bronno van der Holt, Sonja Zweegman, Katja C Weisel, Sandra Croockewit, Anna Jauch, Jens Hillengass, Marian Stevens-Kroef, Marc S Raab, Annemiek Broijl, Gerard M J Bos, Peter Brossart, Paula Ypma, Christine Hanoun, Uta Bertsch, Thomas Hielscher, Hans J Salwender, Christoph Scheid, Hartmut Goldschmidt, Pieter Sonneveld

  • The Immunomodulatory Effect of Different FLT3 Inhibitors on Dendritic Cells.

    Cancers

    Authors: Sebastian Schlaweck, Alea Radcke, Sascha Kampmann, Benjamin V Becker, Peter Brossart, Annkristin Heine

  • Unleashing the potential of eHealth in outpatient cancer care for patients undergoing immunotherapy-a quantitative study considering patients' needs and current healthcare challenges.

    Frontiers in digital health

    Authors: Tobias A W Holderried, Isabel Stasik, Marie-Therese Schmitz, Friederike Schmitz, Tizian K Meyer, Leonie Stauß, Martin Kirschner, Dirk Skowasch, Jennifer Landsberg, Matthias Schmid, Peter Brossart, Martin Holderried